Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (5): 1117-1125    DOI: 10.31083/j.ceog4805180
Original Research Previous articles | Next articles
Searching for biomarkers in the progression from polycystic ovary syndrome to endometrial carcinoma
Zhenzhen Lu1, Ying Gao1, *()
1Department of Gynaecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China
Download:  PDF(19019KB)  ( 33 ) Full text   ( 11 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Polycystic ovary syndrome is a female reproductive system disease closely related to endocrine and highly correlated with the development of endometrial carcinoma in women, it is important to identify the key genes involved in the development of polycystic ovary syndrome. Methods: To identify the hub genes, microarray datasets GSE48301, GSE115810 and GSE3013 were downloaded from Gene Expression Omnibus database. We performed in-depth cross-tabulation bioinformatic analysis to identify differentially expressed genes (DEGs) among four types of endometrial cells in GSE48301 and two endometrial carcinoma datasets GSE115810 and GSE3013, followed by gene ontology, KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment, protein-protein interaction network analysis. Results: Thirteen seed DEGs and 4 significantly expressed DEGs were identified, and potential drugs and mRNAs were found. Conclusion: EDNRA, FBN1, PMP22, SPARC and IGF-1 may be potential and their miRNAs, especially hsa-miR-29a-3p and hsa-miR-29b-3p may be potential biomarkers in the progression from PCOS to endometrial carcinoma.
Key words:  Differentially expressed genes      Endometrial carcinoma      Insulin-like growth factor 1      Polycystic ovary syndrome     
Submitted:  21 March 2021      Accepted:  13 April 2021      Published:  15 October 2021     
*Corresponding Author(s):  Ying Gao     E-mail:  gaoyingpro@163.com

Cite this article: 

Zhenzhen Lu, Ying Gao. Searching for biomarkers in the progression from polycystic ovary syndrome to endometrial carcinoma. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1117-1125.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog4805180     OR     https://ceog.imrpress.com/EN/Y2021/V48/I5/1117

[1] Chang Liu, Minchen Dai, Lei Zhao, Fangfang Wang. The effects of Chinese herbal medicine on the pregnancy outcomes of infertile women with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer: a systematic review and meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1032-1043.
[2] Gonca Özten Dere, Esra Uyanik, Fatih Aktoz, Pınar Çalış, Sezcan Mümüşoğlu, Hakan Yarali, Gürkan Bozdağ. The effect of laparoscopic ovarian drilling on timing of menopause in patients with polycystic ovary syndrome: 29 years of follow-up data[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 590-593.
[3] Hye Won Lee, Lin Ang, Myeong Soo Lee, Kyoung Sun Park, Jin-Moo Lee, Chang-Hoon Lee, Dong Chul Kim, Jeong-Eun Yoo, Seung-Jeong Yang, Tae-Young Choi. Prescription patterns of herbal medicine for polycystic ovarian syndrome in major Korean medicine hospitals: a multicenter retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 649-653.
[4] J. Dun, X. Wang, J. Yang, J. Xu. Clinical practice guidelines on polycystic ovary syndrome: a systematic review and comparative meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 465-471.
[5] Xiao-Tao Huang, Shao-Rong Liang, Lu Wang. Acupuncture combined with Chinese and western medicine in the treatment of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 396-400.
[6] A. M. Maysara, A. T. Nassar, H. K. Jubran. The effect of correction of serum level of vitamin D on hyperandrogenism in women with polycystic ovary syndrome and hypovitaminosis D[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 272-276.
[7] H.M.G. Youssef, E.S. Marei, L.A. Rashed. Long non-coding RNA steroid receptor activator in polycystic ovary syndrome: possible association with metabolic syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 757-762.
[8] M.H. Vieira de Melo, M.T. Albuquerque Barbosa Cabral Micussi, R. Dias de Medeiros, R. Ney Cobucci, T.M. de Oliveira Maranhão, A.K. Gonçalves. Pelvic floor muscle thickness in women with polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 813-816.
[9] Hui-lan Wang, Xia Xu, Zhi-qun Zheng. The expression of Nuclear Factor-κB in a rat model of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 276-279.
[10] P. Marques, F. Ferreira, A. P. Soares, J. Nunes, S. Sousa, A. Aguiar, C. Calhaz-Jorge. Clinico-biochemical characteristics of 229 Portuguese infertile women with polycystic ovary syndrome: clinical relevance and relationship with fertility treatment results[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(6): 812-817.
[11] S. Mihajlovic, M. Vasiljevic, A. Jurisic, D. Kisic-Tepavcevic, D. Dimitrijevic, L. Nejkovic. Predictive value of transvaginal ultrasound score for detection of endometrial malignancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(5): 698-702.
[12] L. H. Sordia-Hernández, P. Ancer Rodríguez, D. Saldivar Rodriguez, S. Trejo Guzmán, E. S. Servín Zenteno, G. Guerrero González, R. Ibarra Patiño. Effect of a low glycemic diet in patients with polycystic ovary syndrome and anovulation - a randomized controlled trial[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(4): 555-559.
[13] S. Hacivelioglu, A. Uysal, A.N. Cakir Gungor, M. Gencer, D.U. Cakir, E. Cosar. The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(1): 32-35.
[14] W. Li, Y. Chen, L. Xu. Association of sympathetic nervous system activity with polycystic ovarian syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 499-506.
[15] L. Hu, H. Shen, Q.F. Wu, L. Tian, M.H. Hu. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(3): 288-292.
No Suggested Reading articles found!